Clinical trials: Lymph Node Metastasis
Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer.
- Trial name
- NCT03733210
- Testing
- Panitumumab-IRDye800, 89-Zirconium (Zr-89) Panitumumab, Pinpoint IR IR9000 fluorescence imaging system (FIS)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Andrei Iagaru
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has…
- Conditions
- Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT02364557
- Testing
- Stereotactic Body Radiotherapy, Surgery
- Where
- 162 sites in United States, Canada and 2 more
- Volunteers
- 129 people
- Sponsor
- NRG Oncology
Non Small Cell Lung Cancer
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
The primary objective of this study is to demonstrate an improvement in Progression-Free Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine plus placebo in chemonaïve (not including an…
- Trial name
- ZELIG (NCT00753714)
- Testing
- ZD6474, Vandetanib, Gemcitabine
- Where
- 15 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Genzyme, a Sanofi Company
SBRT, NSCLC
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
GTI-4711-101 is a Phase I/II study of the safety of GC4711, its effect on in-field tumor response and its potential to reduce radiation-related pulmonary injury due to SBRT for lymph node negative (T1 to T3N0M0) peripheral or…
- Conditions
- SBRT, NSCLC, Non-metastatic
- Trial name
- GRECO-1 (NCT04476797)
- Testing
- GC4711 +SBRT
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- Galera Therapeutics, Inc.
Response To Dengue Exposure
Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine
Background: Dengue is a disease caused by a virus transmitted by mosquitoes in tropical and subtropical regions. Dengue is a leading cause of hospital stays and death in parts of Asia and Latin America, and outbreaks have…
- Trial name
- NCT05691530
- Testing
- rDEN3Δ30/31-7164
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymph Node, Breastcancer
CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer
To establish a predicting system on axillary lymph node metastasis based on peripheral blood CK19mRNA and contrast-enhanced ultrasound.
- Trial name
- CK-CEUS (NCT02992067)
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Zhejiang Cancer Hospital
Low-risk Papillary Thyroid Cancer, Endocrine Malignancy
Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer
Background: Papillary thyroid cancer (PTC) often spreads to lymph nodes in the neck. This can be hard to detect. People often have lymph nodes removed anyway, and researchers want to study if this is a good idea.
- Conditions
- Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer
- Trial name
- NCT02408887
- Testing
- Total Thyroidectomy (TT), Prophylactic central neck lymph node dissection (pCND)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)